Nintedanib(BIBF1120)相关信息

Nintedanib (BIBF 1120) + Docetaxel as Second-Line Therapy in Patients With Stage IIIB/IV or Recurrent NSCLC: Results of the Phase III, Randomised,
Double-Blind LUME-Lung 1 Trial

http://www.boehringer-ingelheim. ... LCC_LUME-Lung_1.pdf

Retrospective Evaluation of the Futility Analysis in LUME-Lung 2, a Randomised, Double-blind, Placebo-controlled Phase III Trial of Nintedanib (BIBF 1120) in Combination with Pemetrexed in NSCLC Patients Progressing after One Prior First-line Chemotherapy

Identification of a Clinical Biomarker for Second-line Combination Treatment with Nintedanib in Adenocarcinoma Non-small Cell Lung Cancer (NSCLC) Patients in Two Phase III Trials

Phase I Study of Oral Nintedanib Combined with Docetaxel in Previously Treated Japanese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

nintedanib_okamoto_119929_P415.pdf (856.92 KB, 下载次数: 102)

2014-7-4 14:48 上传

点击文件名下载附件

Nintedanib (BIBF 1120) plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable  malignant pleural mesothelioma—an international, multicenter, randomized, double-blind, placebo-controlled phase II study

ASCO_2014_-_Meso_Poster.pdf (779.59 KB, 下载次数: 93)

2014-7-4 14:50 上传

点击文件名下载附件

Antiangiogenic-specific adverse events in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (BIBF 1120) and docetaxel

ASCO_2014_-_Safety_Poster.pdf (846.38 KB, 下载次数: 102)

2014-7-4 14:57 上传

点击文件名下载附件

TBD

看了一眼PDF，lume-lung 1临床试验中只有个位数比例的患者接受过一线avastin治疗。

目前来看，这个药在肺腺癌中是一个不错的抗血管生成药物，有希望成为穷人版的avastin。

不知YL何时有

决不放弃11 发表于 2014-7-4 17:33
不知YL何时有

下周